NBI-74330

NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of (125I) CXCL10 and (125I) CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively.

Product Specifications

CAS Number

[855527-92-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/NBI-74330.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N([C@@H](C1=NC2=NC=CC=C2C(N1C3=CC=C(OCC)C=C3)=O)C)CC4=CC=CN=C4)CC5=CC=C(F)C(C(F)(F)F)=C5

Molecular Formula

C32H27F4N5O3

Molecular Weight

605.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Heise CE, et al. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313 (3) :1263-71.|[2]Jopling LA, et al. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol. 2007 Dec;152 (8) :1260-71.|[3]van Wanrooij EJ, et al. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008 Feb;28 (2) :251-7.